Compugen (CGEN)

• Market cap: $159M
• 1 day: -1.20%
• 5 days: -3.53%
• 1 month: 21.48%
• 3 months: 1.86%
• 6 months: 1.86%
• Year to date: -0.61%
• 1 year: -20.00%
• 5 years: -88.96%
• 10 years: -77.41%
• Sector: Healthcare
• Industry: Biotechnology

About: Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Employees: 74

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

18% more capital invested

Capital invested by funds: $18.6M [Q4 2024] → $22.1M (+$3.41M) [Q1 2025]

12% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 17

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

2.53% more ownership

Funds ownership: 13.61% [Q4 2024] → 16.14% (+2.53%) [Q1 2025]

1% more funds holding

Funds holding: 70 [Q4 2024] → 71 (+1) [Q1 2025]

68% less call options, than puts

Call options by funds: $90K | Put options by funds: $278K